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Abstract: Background: Ovarian cancer presents a major clinical challenge in the UK. Glycogen
synthase kinase-3 (GSK-3) has been linked to cancer. This study tested the impact of ShenLingLan
(SLDM) on ovarian cancer cell behaviour and its links to GSK-3. Methods: Fresh ovarian tumours
(n = 52) were collected and processed. Histopathologcial and clinical information were collected
and analysed against GSK-3 transcript levels using quantitative PCR (qPCR). Immortalised ovarian
cancer cells’ protein alterations in response to SLDM were identified using a Kinexus™ protein kinase
array. The effects of SLDM and a combination of SLDM and TWS119 on ovarian cancer cells ability to
attach and migrate were evaluated using electrical cell-substrate impedance sensing (ECIS). Results:
Transcript expression of GSK-3β was significantly increased in ovarian tumours which were poorly
differentiated, patients with recurrence and in patients who had died from ovarian cancer. Treating
SKOV-3 ovarian cells with SLDM reduced GSK-3 expression and GSK-3α (Y279). Treatment with
SLDM reduced ovarian cancer cells ability to attach and migrate, which was further reduced in the
presence of TWS119. Conclusions: This study identified a potential mechanism by which SLDM may
exert anti-metastatic effects. Further work is needed to investigate the in vivo effects SLDM has on
ovarian tumours.
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1. Introduction
Ovarian cancer incidence in women within the UK has increased by 17% since the 1970s and it
is the fifth most common cancer-related death, though it is the seventh most common cancer type
diagnosed [1]. Ovarian cancer is often referred to as the “silent killer” as almost 60% of cases are
diagnosed at an advanced stage of the disease (stages III and IV) [2,3]. Tumour metastasis contributes
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to the poor clinical outcome associated with all cancers, involving several key behaviours; ovarian
cancer cells form metastases by migrating through blood vessels as well as through the peritoneal
cavity, affecting the peritoneum, urothelium, liver and lungs, which may already have occurred at
time of diagnosis and therefore makes the disease harder to treat [4].
Glycogen synthase kinase-3 (GSK-3) has two highly conserved members, GSK3A and GSK3B,
which result in a 51 kDa and 47 kDa protein, respectively [5]. Both have been identified as critical
enzymes involved in a variety of cellular processes, some of which are disrupted in cancer, including
cell cycle progression, differentiation, migration and survival [6]. The overall roles GSK-3 may play in
cancer development and disease progression are complex. Abnormal GSK-3β expression has been
observed in a variety of cancers, including pancreatic, colorectal and ovarian [7–9]. In contrast, in
breast cancer it has been demonstrated that over-expression of GSK-3β may be linked to increased
chemo-sensitivity and reduced tumourigenicity [10,11]. Currently, GSK-3β is known to phosphorylate
over 40 proteins including at least 12 transcription factors [12]. For example, evidence shows that
GSK-3β modulates p53 activity and also affects c-Myc and NFκB activities which can further regulate
many other important genes in cell cycle regulation and oncogenesis [13,14].
ShenLingLan is a traditional medicine, formulated for treating cancer patients and there are early
signs that this medicine benefits these patients. The present study aims to investigate if and how the
medicine may work using a series of methods, in a hope to find and eventually provide scientific
support for using this medicine in patients. ShenLingLan is made of 14 individual herbs, including
Astragalus, Ligustrum lucidum, Ginseng, Ganoderma lucidum, Curcuma, Gynostemma, Atractylodes (fried),
Poria, Cordyceps sinensis, Xu changqing, Eupolyphaga, Panax, diffusa, Scutellaria barbata, Divine Comedy
(fried). Currently, ShenLingLan is used as a formulated capsule, particularly for those who are receiving
chemotherapy. Chen and Wu (2006) demonstrated the safety and efficacy of ShenLingLan in their
clinical trial for chronic hepatitis B and showed that it also affected T-cell function [15].
We recently reported that another Chinese medicine formula, YangZheng XiaoJi, which shares
a good degree of similarities in terms of herbal composition, has important properties by acting on
endothelial cells and cancer cells, together impacting on cancer metastasis [16,17]. The medicine has
also been reported to have a more profound effect on the peritoneal metastatic processes in various
cancer types including pancreatic, ovarian and gastrointestinal cancers [18–20].
In light of these exciting discoveries, we proposed to investigate if ShenLingLan may also exert
similar actions and, if so, by what mechanisms. The study investigated the direct effects of ShenLingLan
on ovarian cancer cell behaviour in vitro and investigated the transcript expression profile of GSK-3β
in our ovarian cohort.
2. Materials and Methods
Materials and cells. Inhibitor to GSK3β, TWS119, was purchased from Tocris (Bristol, UK).
Human ovarian cancer, SKOV3, COV504, OVCAR3, A2780 were purchased from LGC Standard/ATCC
(Southampton, UK).
ShenLingLan extract (SLDM). ShenLingLan was obtained from Yiling Pharmaceuticals
(Shijiazhuang, HeBei, China). It is made of 14 individual herbs, including Astragalus, Ligustrum lucidum,
Ginseng, Ganoderma lucidum, Curcuma, Gynostemma, Atractylodes (fried), Poria, Cordyceps sinensis,
Xu changqing, Eupolyphaga, Panax, diffusa, Scutellaria barbata, Divine Comedy (fried). An extract from
ShenLingLan, named SLDM was prepared using a DMSO-based method that was recently described
in full [21]. Briefly, ShenLingLan formulated powder was added to pure sterile DMSO solution at a
fixed weight/volume ratio. The mixture was placed on a rotating wheel (100 rpm) (Labinco BV, Wolf
Laboratories, York, UK) for 12 h in a cold room at 4 ◦C. The preparation was collected and subject to
centrifugation at 15,000 g, for 20 min at 4 ◦C. The clear supernatant was carefully collected and pooled,
before filtration using filtration filters which had a pore size 0.20 µm (Sartorius Stedim, Sartorius,
Epson, Surrey, UK). The extract was diluted in a balanced salt solution (BSS) and standardised by
quantifying the optical density of the preparation using a spectrophotometer at 450 nm wavelength
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(Biotek, Wolf Laboratory). A master preparation which gave 0.25 OD at 450 nm was stored as the
master stock and so named as SLDM for the subsequent experiments.
2.1. Cell Growth Assay
Cancer cells were first seeded in 96-well tissue culture plates and allowed to adhere. The test
materials and their combinations were then added to the cells, which were subsequently incubated
for a period of 72 h. After removing the culture media, cells were fixed with 4% formalin and stained
with 0.5% Crystal violet. After extensive washing, the staining was extracted with 10% acetic acid and
plates were read on a multiple channel plate reader at 540 nm (BIO-TEK, Elx800, Wolf Laboratories,
York, UK).
2.2. Protein Arrays for Detecting Phosphorylation Changes
Cancer cells at 90% confluence in two T75 tissue culture flasks were washed with BSS buffer
and then placed into a fresh batch of DMEM supplemented with 5% FCS. After 5 h, treatment was
added, again in 5% FCS. After the 5 h period, cells were removed from the flasks with a cell scraper.
The cells were pelleted using a centrifuge at 2500 rpm for 5 min. Lysis buffer was added to the cell
pellets and placed on a spinning wheel for 1 h at 4 ◦C. The lysates were then spun at 12,000 g for
10 min at 4 ◦C. The supernatant were carefully collected and the insolubles discarded. Based on
absorbance, the protein concentration in the cell lysates were quantified using linear regression plot
in Microsoft Excel and then adjusted to 2 mg/mL. The samples were stored at −20 ◦C until use.
Antibody based protein arrays, namely Kinex™, which has 878 capture antibodies spotted on to each
array slide (Kinexus Bioinformatics Ltd., Vancouver, BC, Canada) were used in the present study.
The following are the key parameters collected and used for the data analyses: Globally Normalized
Signal Intensity—Background corrected intensity values were globally normalised. The Globally
Normalized Signal Intensity was calculated by summing the intensities of all the net signal median
values for a sample. Z Scores—Z score transformation corrects data internally within a single sample.
Z Score Difference—The difference between the observed protein Z scores in samples in comparison.
Z Ratios—Divide the Z Score Differences by the SD of all the differences for the comparison. %CFC
defines the changes in intensity between control and treatment samples as the percentage change from
control using globally normalised data.
2.3. Electric Cell-Substrate Impedance Sensing (ECIS)-Based Analyses on Cell Adhesion and Cell Migration
Briefly, 96-well W96E1 microarrays were used on the ECIS Ztheta instrument (Applied Biophysics
Ltd., Troy, NJ, USA). Ovarian cancer cells were added to the wells of the array, cell adhesion was
monitored by immediate tracking, over a range of frequencies (1000 Hz to 64,000 Hz), using automated
modules. The adhesion was analysed using the mathematical modelling methods as previously
described. For cellular migration, confluent ovarian cancer monolayers in the arrays were electrically
wounded (2000 mA for 20 s each), after which the migration of the cells was immediately tracked,
again over a range of frequencies, as the artificial wound closed. All the experiments were conducted
in triplicate.
2.4. Ovarian Cancer Cohort, Analysis of GSK3B Transcript
Fresh frozen ovarian tumours were collected immediately after surgery and stored at−80 ◦C until
use. This was conducted under the approval of the local ethics committee (Peking Cancer Hospital
Ethics Committee, Ethics Number: 2006021) with consent obtained from the patients. Some of the
patients had received chemotherapy or radiation therapy preoperatively. Patient numbers for each
group are in Table 1.
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Table 1. Patients’ clinicopathological information.
Clinical Information Patient Numbers (n)
Stage
1 3
2 3
3 23
4 6
Differentiation
Low 21
Moderate 1
High 2
Tumour Subtype
Adenocarcinoma 44
Transitional 2
Carcinoma 1
Small Cell Ccarcinoma 1
Nonadenoma 5
Metastasis
No metastasis 36
Metastasis 16
Incidence
Incidence free 25
With incidence 27
Survival
Alive 36
Died 9
2.5. Quantitative Analysis of Gene Transcripts in Cells and Tissues
The transcript levels were quantitatively determined by real-time quantitative PCR using StepOne
Plus (Applied Biosystem, Warrington, UK). The quantitative detection was based on the Amplifluor™
probe (Intergen Inc, Oxford, UK) method [22] modified from a previously reported method [23].
Cytokeratin-19 (CK19) was used as the internal house-keeping control. Primer details are given in
Table 2. The reaction was carried out under the following conditions: 94 ◦C for 5 min, 96 cycles at 94 ◦C
for 15 s, 55 ◦C for 35 s and 72 ◦C for 20 s. The levels of the transcripts were generated using an internal
standard that was simultaneously amplified with the samples, and the results are shown in two ways:
levels of transcripts based on equivalent amounts of mRNA, and as a target: CK19 ratio [24].
Table 2. Primer sequences.
Gene Target Primer Sequence (5′-3′)
GSK-3β
Forward AACAGGACATTTCACCTCAG
Reverse ACTGAACCTGACCGTACAGGTGTATACTCCAGCAGACG
CK-19
Forward AGCCACTACTACACGACCAT
Reverse ACTGAACCTGACCGTACATCGATCTGCAGGACAATC
ACTGAACCTGACCGTACA—Z sequence for uniprimer probe.
3. Results
3.1. The Effect of SLDM Treatment on Ovarian Cancer Cell Viabiability
ShenLingLan had little effect on the viability of three of the ovarian cancer cell lines tested (Figure 1).
Over the concentration ranges tested (1:1000 to 1:125,000), SKOV-3, COV-504 and A-2780 cell viability
Medicines 2017, 4, 10 5 of 11
did not significantly differ from the respective DMSO controls (Figure 1A,B,D respectively). When the
highest concentration (1:1000) was used on the OVCAR-3 cells, a significant reduction in cell viability
was seen compared to the matching DMSO control (p = 0.028) (Figure 1C). This significant result
implies that at this concentration in this ovarian cancer cell line, SLDM treatment may cause toxicity.
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growth. At the highest concentration (1:1000) tested SLDM significantly reduced (C) OVCAR‐3 cell 
viability compared to the DMSO control, implying a cytotoxic effect. * p < 0.05 vs. control. 
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Figure 1. Effects of SLDM treatment on ovarian cancer cell viability. At all the concentrations tested,
SLDM treatment had no significant effect on (A) SKOV3, (B) COV504 and (D) A2780 ovarian cell
growth. At the highest concentration (1:1000) tested SLDM significantly reduced (C) OVCAR-3 cell
viability compared to the DMSO control, implying a cytotoxic effect. * p < 0.05 vs. control.
3.2. SL ad a Profound I pact on Cellular Adhesion and igration of varian Cancer Cells
sing the high-throughput screening tool ECIS, it was found that SLDM treatment inhibited both
ovarian cancer cell adhesion and migration in a concentration-dependent manner (Figure 2). The effects
on ovarian cancer cell adhesion were seen in all four of the cell lines tested. In the A2780 and SKOV-3
ovarian cancer cells (Figure 2A,B, respectively), cell attachment was seen at all the concentrations tested;
however, the rate of attachment was reduced with increasing concentrations of SLDM. In contrast,
in the COV-504 and OVCAR-3 cells at the highest concentration tested (1:200), cell attachment was
prevented (Figure 2C,D, respectively).
A similar trend was observed for ovarian cancer cell migration when cells were treated with
SLDM. In all the cell lines tested with increasing concentrations of SLDM, ovarian cancer cell migration
was reduced (Figure 2D–H, respectively).
3.3. Protein Kinase Array Revealed that SLDM Inhibited Phosphorylation of GSK3 in Ovarian Cancer Cells
From the protein array analysis, all the GSK-3 signal strengths showed a reduction in the SKOV-3
ovarian samples treated with SLDM when compared to the untreated control. This change in signal
strength was evident in all of the phosphorylation sites analysed, but particularly at the Y279 site when
presented as a percentage change to the control (Figure 3).
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Figure 2. Concentration-dependent inhibition by SLDM on the adhesion and migration of ovarian cancer cell lines cells. Increasing concentrations, ranging from
1:200 to 1:1,250,000, of SLDM resulted in significantly reduced cell attachment of all four of the ovarian cell lines tested (A): A2780; (B): SKOV-3; (C): COV-504;
(D): OVCAR-3. A similar trend in all of the ovarian cell migration responses after treatment with SLDM; (E): A2780; (F): SKOV-3; (G): COV-504; (H): OVCAR-3.
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Figure 3. Protein array of GSK3 changes in ovarian cells after treatment with SLDM. Signal strength,
indicative of expression, for GSK-3 in SKOV-3 cells treated with SLDM was reduced when compared
to the control. Furthermore, all the phosphorylation sites analysed on the protein array (S278, Y279,
T19 and S21) were also reduced in signal strength compared to the untreated control. The green bars
indicate the changes in signal strength as a representative of percentage control.
3.4. Impact of SLDM and GSK3 Kinase Inhibitor on Cell Migration
Based on the protein array data, further ECIS experiments were done to investigate the potential
combined effects of a GSK-3β small inhibitor (TWS119) and SLDM on ovarian cancer cell attachment
and migration (Figure 4). A2780, COV-504 and SKOV3 ovarian cell attachment was significantly
decreased by SLDM in a dose-dependent manner (from 1:25,000 to 1:1000) and such reduction was
enhanced in the presence of TWS119 (Figure 4A–C, respectively). Similar trends were also seen in
the migratory patterns of the ovarian cancer cells (Figure 4D–F, respectively). The biggest responses,
both in attachment and migration, to the combined treatment of SLDM and TWS119 were observed in
the SKOV-3 cells (Figure 4C,F, respectively).
3.5. GSK3β Expression in Human Ovarian Cancer and the Clinical Implications
Expression of GSK3β was linked to a poor clinical outcome. In this relatively small clinical
cohort, we found that levels of GSK3β transcripts were significantly higher in patients with ovarian
cancer–associated recurrence (p < 0.05 vs. incidence free) and in patients who died of ovarian cancer
(p < 0.05 vs. patients who are alive) (Figure 5B,C, respectively). In addition, poorly differentiated and
non-differentiated tumours had significantly higher levels of GSK3β than tumours which were well
and moderately differentiated (Figure 5A).
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Figure 4. Inhibition of ovarian cell adhesion and migration after treatment with SLDM and TWS119. Treatment of A2780, COV504 and SKOV3 cells with a combination
of SLDM and/or GSK-3β inhibitor TWS119 resulted in decreased cell attachment in all three cell lines ((A), (B) and (C), respectively). Similarly, inhibition of ovarian
cell migration after treatment with SLDM and TWS119 was also observed in all three cell lines tested, A2780, COV504 and SKOV3, respectively ((D), (E) and
(F), respectively).
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Figure 5. Transcript levels of GSK3β in clinical cohort. When normalised to CK19, GSK3β levels were 
significantly increased  in low and non‐differentiated tumours (A). Significantly elevated transcript 
levels were also correlated with recurrence (B) and with those patients that had died from ovarian 
cancer (C). * p < 0.05. 
4. Discussion 
The  roles  GSK‐3  plays  in  a  variety  of  diseases  are  extensive  due  to  the  vast  array  of 
phosphorylation  sites  and  pathways  it  can  regulate. Directional  cell migration  is  a  fundamental 
physiological process which has a wide range of pathways and mediators, one of which  is GSK‐3 
[25]. Within cancer, GSK‐3β has been linked to the process of epithelial to mesenchymal transition 
(EMT). GSK‐3β activity is inhibited by the AKT/Wnt and Hedgehog pathways, whilst GSK‐3β in turn 
has been found to phosphorylate several key oncogenic transcription factors as well as serine residues 
in the EMT marker Snai1 [26]. 
Here we have demonstrated that SLDM inhibits ovarian cell attachment and migration in vitro. 
Furthermore,  in our small clinical cohort,  increased  levels of GSK‐3β were associated with poorly 
differentiated tumours as well as recurrence and those that had died of the disease. Of further interest 
was the observation that the combination of SLDM and the potent TWS119 GSK‐3β inhibitor resulted 
in a decrease in cellular migration. When both the SLDM and TWS119 were combined, reductions in 
cell migration were noticeable in all three of the ovarian cell lines used. It is of further interest to note 
that  the effects of SLDM appeared more significant  in  the  immortalised adenocarcinoma cell  line 
(SKOV‐3) rather than in the epithelial‐serous carcinoma cell line, COV‐504. Ovarian cancer being a 
heterogeneous disease presents challenges in identifying universally efficacious molecular‐targeted 
therapies.  Research  by  Cao  et  al.  (2006)  [7]  identified  that  the  ovarian  cancer  cell  line  SKOV‐3 
produces the most active form of GSK‐3β. In our study, treating COV‐504 cells with TWS‐119 did not 
result in a reduction in cell migration which was observed in the SKOV‐3 and A2780 cells. TWS‐119, 
being a selective target inhibitor, may be limited in inhibiting COV‐504 cell migration in vitro due to 
there potentially being less of the necessary drug target.   
Furthermore,  preliminary  protein  microarray  analysis  identified  several  potential  GSK‐3β 
phosphorylation sites which are targeted after ovarian cancer cells are treated with SLDM. Literature 
identifies that phosphorylation of S21 and Y279 inhibits GSK‐3α activity [27,28]. GSK‐3 is known to 
interact and influence a wide variety of cellular pathways in a range of complex conditions, including 
cancer, and one of the main limitations of emerging GSK‐3 inhibitors is the potential lack of isoform 
selectivity for alpha, beta and alpha/beta forms [29]. Cao et al. (2006) previously demonstrated that 
GSK‐3β drove ovarian cell proliferation both in vitro and in vivo through the increased expression of 
Figure 5. ranscript levels of GSK3β in clinical cohort. hen nor alised to CK19, GSK3β levels ere
significantly increased in lo and non-differentiated tu ours (A). Significantly elevated transcript
levels ere also correlated ith recurrence (B) and with those patients that had died fro ovarian
cancer (C). * p < 0.05.
4. isc ssi
The roles GSK-3 plays in a variety of diseases are xt nsive due to the vast array of phosphoryl tion
sites and pathway it can regulate. Directional cell migrat on is a fundamental physiological process
w ich has a wide range of pathways and mediators, one of which is GSK-3 [25]. W t in cancer,
GSK-3β has bee linked to the proc ss of epithelial to mes nchymal transition (EMT). GSK-3β ctiv ty
is inhibited by the AKT/Wnt and Hedg hog pathways, whilst GSK-3β in turn has been fou d to
phosphorylate several key ncog nic transcription factors as well as serine re idues in the EMT marker
S ai1 [26].
ere e have de onstrate t t i i it i
Further re, i our s al clinical cohort, increase levels of GSK-3β ere associate ith poorly
dif erentiated tumours as wel as recur ence and those that had died of the disease. f f rt er i terest
as the observation that the co bination of SLD and the potent T S119 SK-3β i ibitor resulted
in a . hen both the SLDM and TWS 19 were combined, reductions
in cell migration were noticeable in all three of the ovarian cell lines used. It is of fu ther interest to
note t at the effects of SLDM appeared more significant in the immortalised line
(SK -3) rather than in the epithelial-serous carcino a cel line, COV-504. varian cancer being a
heterogeneo s disease presents chal enges in identifying universal y efficacious olecular-targeted
therapies. Research by Cao et al. (2006) [7] ident fi d that the ovarian cancer cell line SKOV-3 produces
the most active form of GSK-3β. In our study, trea ing COV-504 cells with TWS-119 did not result in
a reduction in cell migration which was observed in th SKOV-3 and A2780 cells. TWS-119, being
a selectiv target inhibitor, may be limit d in inhibiti g COV-504 cell migration in vitro due to th re
potentially being less of the necessary drug target.
Further re, reli i rotei icroarra analysis identified several potential GSK-3β
phosphorylation sites hich are targeted after ovarian cancer cel s are treated ith SL . iterature
identifies that phosphorylatio of S21 and Y279 inhibits GSK-3α activity [27,28]. S -3 is kno n to
interact and influence a ide variety of cel ular path ays in a r e f lex itions, i cl ing
cancer, and one of the main limitations of e erging GSK-3 inhibitors is the potential lack of isofor
selectivity for alpha, beta and alpha/ f [ ]. t al. (20 ) previously de onstrate that
SK-3β rove arian cell roliferation both in itro a i i t r t e i crease ex ression of
cyclin D1 [7,30]. The identification that SLDM targets GSK-3α phosphorylation provides additional
interest as this demonstrates that SLDM has the potential to target both active proteins’ forms of GSK-3.
This inhibitory potential is noteworthy when taken alongside the observations from Fu et al. (2011),
who demonstrated in SKOV-3 cells that GSK-3α messenger RNA increased in paclitaxel-resistant
cells [31]. In a further study, Fu et al. (2014) also identified that aberrant expression of GSK-3α/β was
associated with poor prognosis [32].
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Through exploring the potential anticancer properties of SLDM and identifying, through Kinexus,
phosphorylation events which are potentially induced using this traditional herbal remedy, GSK-3β
was one of the molecular targets which was most affected. Both isomers of GSK-3 have been linked to
ovarian cancer, alpha in chemoresistance and beta with ovarian cancer cell proliferation. Further work
is now required to verify the preliminary protein microarray data and to understand the mechanism of
phosphorylation of GSK-3 which is inhibited by SLDM throughout a wide range of ovarian cancer cell
lines and how these observations in vivo can be used for clinical potential in the future.
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